<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139443">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01764282</url>
  </required_header>
  <id_info>
    <org_study_id>2012ZX10001007-001</org_study_id>
    <nct_id>NCT01764282</nct_id>
  </id_info>
  <brief_title>Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission</brief_title>
  <official_title>A Cluster-randomized Controlled Trial of Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for AIDS/STD Control and Prevention, China CDC</source>
  <oversight_info>
    <authority>China: National Health and Family Planning Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to increase coverage of ART and reduce HIV transmission and
      AIDS-related diseases among serodiscordant couples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early initiation of antiretroviral therapy (ART) could reduce HIV sexually transmission in
      sero-discordant couples by 96% (HPTN 052) and 67% (Chinese National S&amp;T Major Project). And
      the proportion of received HIV ART among HIV serodiscordant couples is still low in China
      (53.3% by Sep 30, 2011).

      The purposes of this study are:

        1. Increase coverage of ART among HIV serodiscordant couples by at least 50%, comparing
           with the control group by 2015 .

        2. Reduce HIV transmission among serodiscordant couples by at least 50%, comparing with
           the control group by 2015 .

        3. Reduce AIDS-related diseases among serodiscordant couples by at least 50%, comparing
           with the control group by 2015.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>HIV seroconversion rate of HIV negatives among HIV serodiscordant couples</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV positives receiving ART among HIV serodiscordant couples</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of AIDS-related diseases of HIV positives among serodiscordant couples</measure>
    <time_frame>up to 2  years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>HIV</condition>
  <condition>ART</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV serodiscordant couples in intervention arm can receive the following intervention services: ART promotion, Couple testing and consulting promotion, and Condom use promotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Comprehensive intervention group</intervention_name>
    <description>ART promotion, Couple testing and consulting promotion, and Condom use promotion</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Couples are required to have a stable relationship and live together in the last 3
             months;

          -  Older than 18 years and younger than 60 years; without regard to CD4 count;

          -  Open cohort(any newly diagnosed serodiscordant couples who are eligible for treatment
             will be included during the study period).

        Exclusion Criteria:

          -  Couples are not have a stable relationship or do not live together in the last 3
             months;

          -  Younger than 18 years old.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuyou Wu, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for AIDS/STD Control and Prevention, China CDC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zunyou Wu, MD, PHD</last_name>
    <phone>86-10-58900900</phone>
    <email>wuzunyou@chinaaids.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yurong Mao, MD, PHD</last_name>
    <phone>86-10-58900985</phone>
    <email>maoyr@chinaaids.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention,Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning, Guilin, Laibin, Qinzhou</city>
        <state>Guangxi</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuying Zhu, MD</last_name>
      <phone>0771-2518960</phone>
      <email>zhuqiuying2003@126.com</email>
    </contact>
    <contact_backup>
      <last_name>He Jiang, MD</last_name>
      <phone>0771-2518339</phone>
      <email>21472948@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qiuying Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Henan Province</name>
      <address>
        <city>Zhumadian</city>
        <state>Henan</state>
        <zip>463000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Wang, MD</last_name>
      <phone>0371-68089112</phone>
      <email>wangzhe@hncdc.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhe Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Sichuan Province</name>
      <address>
        <city>Liangshan</city>
        <state>Sichuan</state>
        <zip>615000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linglin Zhang, MD</last_name>
      <phone>028-85589207</phone>
      <email>weirzhang@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Linglin Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Urumchi, Ili</city>
        <state>Xinjiang</state>
        <zip>830002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjian Ni, MD</last_name>
      <phone>86-991-2621390</phone>
      <email>xjnmj@126.com</email>
    </contact>
    <investigator>
      <last_name>Mingjian Ni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Yunnan Province</name>
      <address>
        <city>Kunming, Dehong, Wenshan, Honghe</city>
        <state>Yunnan</state>
        <zip>650022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manhong Jia, MD</last_name>
      <phone>0871-3626304</phone>
      <email>jmanhong@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yong Zhang, MD</last_name>
      <phone>0871-3630775</phone>
    </contact_backup>
    <investigator>
      <last_name>Manhong Jia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nmp.gov.cn/index.htm</url>
    <description>National Science and Technology Project</description>
  </link>
  <results_reference>
    <citation>Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, Zhou S, Bulterys M, Zhu H, Chen RY. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011 Jul;11(7):516-24. doi: 10.1016/S1473-3099(11)70097-4.</citation>
    <PMID>21600849</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis. 2010 May 15;50 Suppl 3:S85-95. doi: 10.1086/651478. Review.</citation>
    <PMID>20397961</PMID>
  </results_reference>
  <results_reference>
    <citation>Stephenson R, Barker J, Cramer R, Hall MA, Karita E, Chomba E, Vwalika C, Allen S. The demographic profile of sero-discordant couples enrolled in clinical research in Rwanda and Zambia. AIDS Care. 2008 Mar;20(3):395-405. doi: 10.1080/09540120701593497.</citation>
    <PMID>18351489</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>December 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>serodiscordant couples HIV sero-conversion</keyword>
  <keyword>anti-retroviral therapy</keyword>
  <keyword>intervention</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
